Drug class profile · refreshed daily from federal data

Dopamine and Norepinephrine Reuptake Inhibitor

1 molecule in this class, $32.7M combined CY2024 Part D spend across 31K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Dopamine and Norepinephrine Reuptake Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class
1tracked in Part D
CY24 Part D spend
$32.7Mcombined across class
Total Rx claims
31K7K unique beneficiaries
Generic mfrs (active)
0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard
01
Solriamfetol
Brand: SUNOSI · 31K Part D claims (CY24) · 7K beneficiaries · First FDA approval:
Brand-only (no generics) 102 plans require PA
Low NADAC$31.33
Avg plan cost$31.33
Part D spend $32.7M spread, current vs floor
Class share
100%
of class CY24 spend
View profile →